The firms will validate histopathology biomarkers related to bladder cancer using clinical data and tissue samples captured during cystoscopy.

Last week, readers were most interested in a story about ASCO's decision not to recommend the use of Grail's MCED test in light of NHS trial data.

Under the repurchase program, the company may repurchase shares through open market purchases, in privately negotiated transactions, or by other means.

NEW YORK – A new test from Abbott, developed in collaboration with the Mayo Clinic, uses a self-administered tampon to collect samples to test for endometrial cancer. The test is the fruition of about ...

The companies will initially offer C2N's PrecivityAD test in Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.

NEW YORK – Roche subsidiary Foundation Medicine announced on Tuesday that its FoundationOne CDx assay has received US Food and Drug Administration approval for use as a companion diagnostic with Roche ...

Under the agreement, NDT has an exclusive worldwide license for diagnostic use of a panel of nine antibodies to different tau protein forms.

NEW YORK – Bluejay Diagnostics announced on Tuesday definitive agreements for the purchase and sale of its stock and warrants that are expected to raise up to $23.6 million in gross proceeds. Acton, ...

NEW YORK – Biotechnology company Toby said on Tuesday that it received breakthrough device designation from the US Food and Drug Administration for its urine-based Alzheimer's disease test. The test ...

NEW YORK – UK diagnostics firm iFAST said on Tuesday that it has closed a £5 million ($6.7 million) financing round to expand the rollout of its technology in the UK. Additionally, the company has ...